Noile-Immune Biotech Inc. (4893.T)
JPY 163.0
(-1.81%)
JPY 163.0
(-1.81%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Operating Cash Flow | -873.07 Million | -107.17 Million | -777.14 Million | -300.64 Million |
| Net Income | -1.12 Billion | -384.2 Million | -792.61 Million | -630.97 Million |
| Depreciation & Amortization | - | - | - | 12.8 Million |
| Deferred income taxes | - | - | - | - |
| Stock-based compensation | - | - | - | - |
| Change in working capital | -95.38 Million | 27.58 Million | 26.4 Million | 118.93 Million |
| Other non-cash items | 351.84 Million | 256.08 Million | -10.62 Million | 15.08 Million |
| Investing Cash Flow | -5.31 Million | - | -4.03 Million | - |
| Investments in PPE | - | - | - | - |
| Acquisitions | - | - | - | - |
| Investment purchases | - | - | -4.03 Million | - |
| Sales/Maturities of investments | - | - | - | - |
| Other Investing Activities | -5.31 Million | - | -4.03 Million | - |
| Financing Cash Flow | 1.91 Billion | 487.61 Million | 2.37 Billion | 996.34 Million |
| Debt repayment | - | - | - | - |
| Dividends payments | - | - | - | - |
| Common Stock Repurchased | - | - | - | - |
| Common Stock Issuance | 2.5 Billion | 498.31 Million | 2.37 Billion | 996.34 Million |
| Other Financing Activities | 1.91 Billion | 1.83 Million | - | - |
| Accounts receivables | -70.53 Million | 53.03 Million | -1.07 Million | 185.58 Million |
| Accounts payables | - | -8.44 Million | -4.92 Million | -44.8 Million |
| Inventory | -16.97 Million | 344 Thousand | 7.11 Million | -10.01 Million |
| Other working capital | 277 Million | -44.61 Million | -10.44 Million | 3.5 Million |
| Cash at beginning of period | 4.52 Billion | 4.14 Billion | 2.54 Billion | 1.85 Billion |
| Cash at end of period | 5.55 Billion | 4.52 Billion | 4.14 Billion | 2.54 Billion |
| Capital Expenditure | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - |
| Net cash flow / Change in cash | 1.03 Billion | 380.43 Million | 1.59 Billion | 695.7 Million |
| Free Cash Flow | -873.07 Million | -107.17 Million | -777.14 Million | -300.64 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -343 Million | -340 Million | -1.12 Billion | -280 Million | -17 Million | -339 Million |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | - | -95.38 Million | - | - | - |
| Other non-cash items | 343 Million | 340 Million | 351.84 Million | 280 Million | 17 Million | 339 Million |
| Investing Cash Flow | - | - | -5.31 Million | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | -5.31 Million | - | - | - |
| Financing Cash Flow | - | - | 1.91 Billion | - | - | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 2.5 Billion | - | - | - |
| Other Financing Activities | - | - | 1.91 Billion | - | - | - |
| Accounts receivables | - | - | -70.53 Million | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | -16.97 Million | - | - | - |
| Other working capital | - | - | 277 Million | - | - | - |
| Cash at beginning of period | - | - | 4.52 Billion | - | - | - |
| Cash at end of period | - | - | 5.55 Billion | - | - | - |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | - | 1.03 Billion | - | - | - |
| Free Cash Flow | - | - | -873.07 Million | - | - | - |
AIW
0A23
LSB
122990
HUMBLE
090710